Table 1 The list of the significantly altered PPI networks and their related top diseases and functions analysed employing the Ingenuity Pathways Analysis software in DES subgroups compared to CTRL.
From: Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients
Groups | Increment | Decrement | Score | Focus molecules | Top diseases and functions |
|---|---|---|---|---|---|
DRYlip vs. CTRL | IGHA1, SCGB1D1, SCGB2A1 | ALB, CSTB, HP, IGHG1, KRT1, KRT9, KRT10, ORM2, SERPINA1 | 30 | 12 | Dermatological diseases and conditions, developmental disorders |
A2M, ENO1, IGLL1/IGLL5, LCN2 | AKR1A1, ANXA2, GDI2, HP, HSPB1, SERPINB1, ZG16B | 27 | 11 | Digestive system development and function | |
DRYaq vs. CTRL | ALB, ANXA1, ANXA5, CFH, GC, GSN, HP, IGHG1, IGHG2, MDH1, ORM1, ORM2, PFN1, PPIA, S00A8, S100A9, SERPINA1, TF, TTR | ACTB, CLU, HSPA1A/HSPA1B, HSPG2, IGHA1, KRT1, KRT9, S100A9, ZG16B | 71 | 28 | Cellular movement, immune cell trafficking, metabolic disease |
A2M, ASS1, CSTB, FABP5, FBP1, GLOD4, PIGR | CTSB, DMBT1, HSPB1, IGHA2, LACRT, PKM, PRR4, SCGB1D1 | 31 | 15 | Hereditary disorder, neurological disease, organismal injury and abnormalities | |
AKR1C1/AKR1C2, ALDH3A1, ANXA3, ENO1, GSTP1, PARK7, PEBP1, PGK1, PRDX1, SFN | ALDH1A1, AZGP1, TCN1 | 26 | 13 | Small molecule biochemistry, cancer, endocrine system disorders | |
DRYaqlip vs. CTRL | ALB, ANXA1, CFH, IGHG1, IGHG2, ITIH4, ORM1, PARK7, PIGR, RBP4, S100A8, S100A), S100A11, TF, TPI1, YWHAZ | AZGP1, CLU, DMBT1, HSPG2, IGHA1, KRT1, KRT9, KRT10, LTF, LYZ, MDH1, TCN1 | 73 | 29 | Antimicrobial response, inflammatory response, humoral immune response |
A2M, ALDOA, ANXA2, ANXA5, CSTB, ENO1, GSN, GSTP1, PFN1, PPIA, SERPINB1, SFN, TGM2 | ACTB, CTSB, HSPB1, PGK1 | 36 | 17 | Cellular movement, inflammatory response, neurological disease | |
AKR1A1, FABP5, GLOD4, PEBP1, PRDX1 | CST4, LACRT, LYZ, PKM, PRR4, SCGB1D1, SCGB2A1, ZG16B | 25 | 13 | Carbohydrate metabolism, small molecule biochemistry, cardiovascular disease |
